companydata.dkcompanydata.dk

VELOXIS PHARMACEUTICALS A/S: Financial statements 2022

CVR: 26527767

Source: annual report 2022, Danish Business Authority

01/04/2021 – 31/03/2022

VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2022. In 2022, the company reported a gross profit of USD 0 and a net result of USD 2,060,000 compared with USD 1,057,461,000 the year before. Equity in the 2022 report amounted to USD 2,881,000. The solvency ratio was 74.2%.

Revenue
USD 0
Profit/Loss
USD 2,060,000
Equity
USD 2,881,000
Total Assets
USD 3,885,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20220 USD0 USD2.1M USD2.9M USD-
202145.3M USD45.3M USD1.1B USD1.3B USD-
201839.5M USD31.6M USD-5.3M USD4.6M USD-
201730.2M USD25M USD-9.5M USD5.3M USD-
20169.2M USD6.2M USD-10.1M USD10.2M USD-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on VELOXIS PHARMACEUTICALS A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Yusuke Hiramatsu joins the board of VELOXIS PHARMACEUTICALS A/SAug 31, 2022

As of August 31, 2022, Yusuke Hiramatsu has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.

Hiroki Ideguchi leaves the board of VELOXIS PHARMACEUTICALS A/SAug 31, 2022

As of August 31, 2022, Hiroki Ideguchi has left the board of directors of VELOXIS PHARMACEUTICALS A/S.

About VELOXIS PHARMACEUTICALS A/S

VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.

Source: annual report 2026, Danish Business Authority